EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome

Ikuko Aiba, Yuichi Hayashi, Takayoshi Shimohata, Mari Yoshida, Yuko Saito, Koichi Wakabayashi, Takashi Komori, Masato Hasegawa iD, Takeshi Ikeuchi iD, Aya M Tokumaru, Keita Sakurai, Shigeo Murayama and 42 more

Brain Communications · 2023-11-01 · 5 (6)

DOI: 10.1093/braincomms/fcad296 ↗

At a glance

Journal article in Brain Communications, published online on 2023-11-03. Written by Ikuko Aiba and 53 co-authors. Institution: Department of Neurology, NHO Higashinagoya National Hospital, Nagoya, Aichi 465-8620, Japan. Cited 39 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of Health, Labour and Welfare, Japan, Japan Agency for Medical Research and Development.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The clinical presentation of corticobasal degeneration is diverse, while the background pathology of corticobasal syndrome is also heterogeneous. Therefore, predicting the pathological background of corticobasal syndrome is extremely difficult. Herein, we investigated the clinical findings and course in patients with pathologically, genetically and biochemically verified corticobasal degeneration and corticobasal syndrome with background pathology to determine findings suggestive of background disorder. Thirty-two patients were identified as having corticobasal degeneration. The median intervals from the initial symptoms to the onset of key milestones were as follows: gait disturbance, 0.0 year; behavioural changes, 1.0 year; falls, 2.0 years; cognitive impairment, 2.0 years; speech impairment, 2.5 years; supranuclear gaze palsy, 3.0 years; urinary incontinence, 3.0 years; and dysphagia, 5.0 years. The median survival time was 7.0 years; 50% of corticobasal degeneration was diagnosed as corticobasal degeneration/corticobasal syndrome at the final presentation. Background pathologies of corticobasal syndrome (n = 48) included corticobasal degeneration (33.3%), progressive supranuclear palsy (29.2%) and Alzheimer’s disease (12.5%). The common course of corticobasal syndrome was initial gait disturbance and early fall. In addition, corticobasal degeneration–corticobasal syndrome manifested behavioural change (2.5 years) and cognitive impairment (3.0 years), as the patient with progressive supranuclear palsy–corticobasal syndrome developed speech impairment (1.0 years) and supranuclear gaze palsy (6.0 years). The Alzheimer’s disease–corticobasal syndrome patients showed cognitive impairment (1.0 years). The frequency of frozen gait at onset was higher in the corticobasal degeneration–corticobasal syndrome group than in the progressive supranuclear palsy–corticobasal syndrome group [P = 0.005, odds ratio (95% confidence interval): 31.67 (1.46–685.34)]. Dysarthria at presentation was higher in progressive supranuclear palsy–corticobasal syndrome than in corticobasal degeneration–corticobasal syndrome [P = 0.047, 6.75 (1.16–39.20)]. Pyramidal sign at presentation and personality change during the entire course were higher in Alzheimer’s disease–corticobasal syndrome than in progressive supranuclear palsy–corticobasal syndrome [P = 0.011, 27.44 (1.25–601.61), and P = 0.013, 40.00 (1.98–807.14), respectively]. In corticobasal syndrome, decision tree analysis revealed that ‘freezing at onset’ or ‘no dysarthria at presentation and age at onset under 66 years in the case without freezing at onset’ predicted corticobasal degeneration pathology with a sensitivity of 81.3% and specificity of 84.4%. ‘Dysarthria at presentation and age at onset over 61 years’ suggested progressive supranuclear palsy pathology, and ‘pyramidal sign at presentation and personality change during the entire course’ implied Alzheimer’s disease pathology. In conclusion, frozen gait at onset, dysarthria, personality change and pyramidal signs may be useful clinical signs for predicting background pathologies in corticobasal syndrome.

Subjects

Author keywords

clinical coursecorticobasal degenerationcorticobasal syndromediagnosispathology

Authors and institutions

  • Department of Neurology, NHO Higashinagoya National Hospital, Nagoya, Aichi 465-8620, Japan.
  • Department of Neurology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
  • Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi 480-1195, Japan.
  • Department of Neuropathology (the Brain Bank for Aging Research), Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo 173-0015, Japan.
  • Department of Pathology and Laboratory Medicine, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan.
  • Department of Neuropathology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan.

ORCID profiles: Masato Hasegawa, Takeshi Ikeuchi, Masato Kanazawa, Tatsushi Toda

Funding

  • Ministry of Health, Labour and Welfare, Japan
  • Japan Agency for Medical Research and Development

Cite

APA

Aiba, I., Hayashi, Y., Shimohata, T., Yoshida, M., Saito, Y., Wakabayashi, K., Komori, T., Hasegawa, M., Ikeuchi, T., Tokumaru, A. M., Sakurai, K., Murayama, S., Hasegawa, K., Uchihara, T., Toyoshima, Y., Saito, Y., Yabe, I., Tanikawa, S., Sugaya, K., …, & J-VAC study group (2023). Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome. Brain Communications, 5(6). https://doi.org/10.1093/braincomms/fcad296

Vancouver

Aiba I, Hayashi Y, Shimohata T, Yoshida M, Saito Y, Wakabayashi K, et al. Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome. Brain Communications. 2023;5(6). doi:10.1093/braincomms/fcad296

BibTeX
@article{Aiba2023,
  author = {Aiba, Ikuko and Hayashi, Yuichi and Shimohata, Takayoshi and Yoshida, Mari and Saito, Yuko and Wakabayashi, Koichi and Komori, Takashi and Hasegawa, Masato and Ikeuchi, Takeshi and Tokumaru, Aya M and Sakurai, Keita and Murayama, Shigeo and Hasegawa, Kazuko and Uchihara, Toshiki and Toyoshima, Yasuko and Saito, Yufuko and Yabe, Ichiro and Tanikawa, Satoshi and Sugaya, Keizo and Hayashi, Kentaro and Sano, Terunori and Takao, Masaki and Sakai, Motoko and Fujimura, Harutoshi and Takigawa, Hiroshi and Adachi, Tadashi and Hanajima, Ritsuko and Yokota, Osamu and Miki, Tomoko and Iwasaki, Yasushi and Kobayashi, Michio and Arai, Nobutaka and Ohkubo, Takuya and Yokota, Takanori and Mori, Keiko and Ito, Masumi and Ishida, Chiho and Tanaka, Masaharu and Idezuka, Jiro and Kanazawa, Masato and Aoki, Kenju and Aoki, Masashi and Hasegawa, Takafumi and Watanabe, Hirohisa and Hashizume, Atsushi and Niwa, Hisayoshi and Yasui, Keizo and Ito, Keita and Washimi, Yukihiko and Mukai, Eiichiro and Kubota, Akatsuki and Toda, Tatsushi and Nakashima, Kenji and J-VAC study group, J-VAC study group},
  title = {Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome},
  journal = {Brain Communications},
  year = {2023},
  volume = {5},
  number = {6},
  doi = {10.1093/braincomms/fcad296}
}
Start for free →